Climb Bio Reports $12.9 Million Net Loss in Q3 2025, Highlights R&D Expenses and Clinical Trials

Climb Bio, Inc. reported a net loss of $12.9 million for the third quarter of 2025, compared to a loss of $8.9 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $42.3 million, a significant improvement from the $65.5 million loss reported for the same period in 2024. The increase in losses for the quarter was attributed primarily to higher research and development expenses, which rose to $9.1 million from $6.2 million year-over-year, driven by costs associated with advancing clinical trials for its lead product candidate, budoprutug. The company has not generated any revenue from product sales since its inception and has an accumulated deficit of $272.2 million as of September 30, 2025.

In terms of operational developments, Climb Bio completed the acquisition of Tenet Medicines, Inc. on June 27, 2024, which was accounted for as an asset acquisition. This acquisition included the rights to budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. The company has initiated clinical trials for budoprutug in multiple countries, including a Phase 2 trial for primary membranous nephropathy (pMN) and a Phase 1b/2a trial for immune thrombocytopenia (ITP). Additionally, Climb Bio entered into a technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. for the development and commercialization of CLYM116 outside of Greater China.

Climb Bio's financial position has changed significantly since the previous fiscal period, with cash and cash equivalents decreasing to $25.8 million from $87.2 million at the end of 2024. The company also reported total current assets of $90.9 million, down from $154.9 million at the end of the previous year. The decrease in cash reserves is attributed to ongoing operational expenses and investments in research and development. The company anticipates that its available cash, cash equivalents, and marketable securities of $175.8 million will be sufficient to meet its projected operating requirements for at least the next twelve months.

Looking ahead, Climb Bio expects to continue incurring significant losses as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company has indicated that it may need to raise additional capital in the future to fund its operations, which could include equity offerings or collaborations. The success of its product candidates, particularly budoprutug and CLYM116, remains contingent on obtaining regulatory approvals and successfully commercializing these therapies. The company has also acknowledged the risks associated with competition in the biotechnology sector, as well as the potential impact of regulatory changes and market conditions on its business operations.